Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons

(2011) Christoph Thomas et al.   CELL

Interaction between oxidative stress and chemokines: Possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis

(2011) Dilip Shah et al.   IMMUNOBIOLOGY

Type I interferon system activation and association with disease manifestations in systemic sclerosis

(2010) M.-L. Eloranta et al.   ANNALS OF THE RHEUMATIC DISEASES

Irreversible Pulmonary Hypertension Associated with the use of Interferon Alpha for Chronic Hepatitis C

(2010) Sonu Dhillon et al.   DIGESTIVE DISEASES AND SCIENCES

Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report

(2009) AH Ledinek et al.   Multiple Sclerosis Journal